Hosted on MSN23d
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first gene therapy to win clearance in the U.S. The agency greenlighted ...
Yahoo23d
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The ...
Becker's Hospital Review20d
FDA approves Pfizer's 1st gene therapy
Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S. On April 26, Beqvez (fidanacogene elaparvovec-dzkt) won approval to treat some adults with moderate-to ...
GEN21d
FDA Approves Pfizer’s One-Time Gene Therapy BEQVEZ for Hemophilia B
Patients with moderate to severe hemophilia B can now take Pfizer’s BEQVEZ (fidanacogene elaparvovec-dzkt) with the approval of the FDA. Hemophilia B is an inherited bleeding disorder that ...
biopharma-reporter19d
Pfizer heralds “paradigm shift” in hemophilia B gene therapy with FDA approval
Pfizer's groundbreaking $3.5 million gene therapy for Hemophilia B just got FDA approval. Here’s what it means for patients ...
LinkedIn23d
Pfizer gene therapy gets FDA OK
Pfizer won approval from the Food and Drug Administration for its first gene therapy, Beqvez, to be used by patients with the rare bleeding disorder, hemophilia B. The drug, a one-time treatment ...
Reuters23d
US FDA approves Pfizer's gene therapy for rare bleeding disorder
, opens new tab gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein. People with ...
healthandpharma23d
Transformative One-Time Gene Therapy: FDA Approves Pfizer's BEQVEZ, for Hemophilia B
Pfizer announced that the US Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with moderate to severe hemophilia B. The ...
Dunya News22d
US FDA approves Pfizer gene therapy for rare bleeding disorder
WASHINGTON (Reuters) – The US Food and Drug Administration approved Pfizer's gene therapy for haemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires ...
The Pharma Letter23d
FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia B
The US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt), a gene therapy for hemophilia B. Developed by US pharma giant Pfizer (NYSE: PFE), Beqvez is authorized ...
Business Wire23d
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of ...